Pharmaceutical company Starpharma Holdings Limited (ASX:SPL) has expanded its relationship with global biopharmaceutical company AstraZeneca.
Both companies have inked a second expanded agreement in the field of cancer medicine using Starpharma’s proprietary DEP dendrimer drug delivery technology.
The new deal will see the application of Starphama’s technology to a cancer drug following on from an evaluation by AstraZeneca which began in September 2012.
AstraZeneca will provide funding for a preclinical stage cancer research program to be conducted jointly.
Starpharma advises its DEP technology improves the performance of pharmaceuticals.
Starpharma Holdings booked a net loss of $5.6 million in the first half of the 2014 financial year.
